{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:56:37Z","timestamp":1794243397341,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Germline\n                    <jats:italic>BRCA1<\/jats:italic>\n                    and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were introduced into clinical practice in 2018. Limited evidence about their routine clinical use highlights the importance of this analysis. We provide a real-world analysis for PARP-inhibitor use in ABC patients treated within the prospective German PRAEGNANT registry (NCT02338167). 152 patients with ABC receiving a PARP-inhibitor were included. Real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) were calculated for all patients using the Kaplan\u2013Meier method. Subgroups (line of therapy, metastasis timing, hormone receptor (HR) status, treatment: olaparib, talazoparib, among others), germline\n                    <jats:italic>BRCA1<\/jats:italic>\n                    ,\n                    <jats:italic>BRCA2<\/jats:italic>\n                    and\n                    <jats:italic>PALB2<\/jats:italic>\n                    mutations and adverse events (AEs) were analyzed. The median rwPFS was 6.2 months (95% CI, 4.8\u20137.9) and the median rwOS was 17.1 months (95% CI, 14.4\u201322.3). Line of therapy, HR status and treatment (olaparib versus talazoparib) appeared to especially affect both rwPFS and rwOS. Among patients with a reported germline mutation, 36.1% had a\n                    <jats:italic>BRCA1<\/jats:italic>\n                    , 62.9% a\n                    <jats:italic>BRCA2<\/jats:italic>\n                    and 1.0% a\n                    <jats:italic>PALB2<\/jats:italic>\n                    mutation. In summary, outcomes were comparable to those reported in pivotal trials despite later-line use of PARP-inhibitors in this analysis.\n                  <\/jats:p>","DOI":"10.1038\/s41523-026-00947-8","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T14:08:16Z","timestamp":1775916496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer\u2014Results from the prospective PRAEGNANT registry"],"prefix":"10.1038","volume":"12","author":[{"given":"Manuel","family":"H\u00f6rner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Uhrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00eb","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Philipp","family":"Cieslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara M.","family":"Tretschock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dannehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Dimpfl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Ehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Eichst\u00e4dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Englisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melitta B.","family":"K\u00f6pke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kr\u00fcckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Sch\u00e4ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Sych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Tegeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Princk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin C.","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang W.","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christian","family":"Kolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin-Andrei","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diethelm","family":"Wallwiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Belleville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallwiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"947_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med."},{"key":"947_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"947_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson, M. E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558\u2013566 (2019).","journal-title":"Ann. Oncol."},{"key":"947_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton, J. K. et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol. 31, 1526\u20131535 (2020).","journal-title":"Ann. Oncol."},{"key":"947_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.2024.42.16_suppl.1021","volume":"42","author":"NM Tung","year":"2024","unstructured":"Tung, N. M. et al. TBCRC 048 (olaparib expanded) expansion cohorts: phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. J. Clin. Oncol. 42, 1021\u20131021 (2024).","journal-title":"J. Clin. Oncol."},{"key":"947_CR6","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"947_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","volume":"3","author":"JJ Gruber","year":"2022","unstructured":"Gruber, J. J. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat. Cancer 3, 1181\u20131191 (2022).","journal-title":"Nat. Cancer"},{"key":"947_CR8","unstructured":"(AGO), A.G.O. Endokrine und zielgerichtete Therapie \u2013 Mamma 2025. 2025 [cited 2025 July 6]; Available from: https:\/\/www.ago-online.de\/fileadmin\/ago-online\/downloads\/_leitlinien\/kommission_mamma\/2025\/D_PDF\/AGO_2025D_18_Endokrine_und_zielger_Therapie_met.pdf."},{"key":"947_CR9","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry, N. L. et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J. Clin. Oncol. 40, 3205\u20133221 (2022).","journal-title":"J. Clin. Oncol."},{"key":"947_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/a-2515-2366","volume":"85","author":"D L\u00fcftner","year":"2025","unstructured":"L\u00fcftner, D. et al. Update breast cancer 2024 Part 3 - Patients with advanced stage breast cancer. Geburtshilfe Frauenheilkd. 85, 507\u2013519 (2025).","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"947_CR11","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"PM Morice","year":"2021","unstructured":"Morice, P. M. et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 8, e122\u2013e134 (2021).","journal-title":"Lancet Haematol."},{"key":"947_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-023-07165-x","volume":"204","author":"J Balma\u00f1a","year":"2024","unstructured":"Balma\u00f1a, J. et al. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Res. Treat. 204, 237\u2013248 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"947_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3332\/ecancer.2023.1634","volume":"17","author":"FE Petracci","year":"2023","unstructured":"Petracci, F. E. et al. LuciA-15 - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and\/or somatic mutation of BRCA genes or homologous recombination repair related genes. Ecancermedicalscience 17, 1634 (2023).","journal-title":"Ecancermedicalscience"},{"key":"947_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1634\/theoncologist.2015-0002","volume":"20","author":"M Bonotto","year":"2015","unstructured":"Bonotto, M. et al. Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? Oncologist 20, 719\u201324 (2015).","journal-title":"Oncologist"},{"key":"947_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson, M. E. et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur. J. Cancer 184, 39\u201347 (2023).","journal-title":"Eur. J. Cancer"},{"key":"947_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2021.03.029","volume":"152","author":"KA Gelmon","year":"2021","unstructured":"Gelmon, K. A. et al. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur. J. Cancer 152, 68\u201377 (2021).","journal-title":"Eur. J. Cancer"},{"key":"947_CR17","doi-asserted-by":"publisher","unstructured":"Safonov, A. et al. Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer. Preprint at https:\/\/doi.org\/10.1101\/2024.02.05.578934 (2024).","DOI":"10.1101\/2024.02.05.578934"},{"key":"947_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","volume":"54","author":"A Schneeweiss","year":"2020","unstructured":"Schneeweiss, A. et al. Initial experience with CDK4\/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 54, 88\u201395 (2020).","journal-title":"Breast"},{"key":"947_CR19","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.20.01200","volume":"39","author":"PA Fasching","year":"2021","unstructured":"Fasching, P. A. et al. Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer -association with patient and disease characteristics and effect on prognosis. J. Clin. Oncol. 39, 1619\u20131630 (2021).","journal-title":"J. Clin. Oncol."},{"key":"947_CR20","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-24-4221","volume":"31","author":"S Guiu","year":"2025","unstructured":"Guiu, S. et al. Combination of olaparib, durvalumab, and fulvestrant in patients with advanced ER+\/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial. Clin. Cancer Res. 31, 4633\u20134643 (2025).","journal-title":"Clin. Cancer Res."},{"key":"947_CR21","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"947_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer, C. E. Jr et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann. Oncol. 33, 1250\u20131268 (2022).","journal-title":"Ann. Oncol."},{"key":"947_CR23","unstructured":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4\/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+\/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01). 2025 2025\u201311\u201328 [cited 2025 2025-10-14]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06380751#contacts-and-locations."},{"key":"947_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/009286150804200502","volume":"42","author":"NA Dreyer","year":"2008","unstructured":"Dreyer, N. A. et al. Good practices for handling adverse events detected through patient registries. Drug Inf. J. 42, 421\u2013428 (2008).","journal-title":"Drug Inf. J."},{"key":"947_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0034-1396215","volume":"75","author":"PA Fasching","year":"2015","unstructured":"Fasching, P. A. et al. Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network. Geburtshilfe Frauenheilkd. 75, 41\u201350 (2015).","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"947_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.breast.2017.10.002","volume":"37","author":"AD Hartkopf","year":"2018","unstructured":"Hartkopf, A. D. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 37, 42\u201351 (2018).","journal-title":"Breast"},{"key":"947_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.breast.2017.08.008","volume":"37","author":"V M\u00fcller","year":"2018","unstructured":"M\u00fcller, V. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 37, 154\u2013160 (2018).","journal-title":"Breast"},{"key":"947_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10549-016-3850-8","volume":"158","author":"A Hein","year":"2016","unstructured":"Hein, A. et al. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. Breast Cancer Res. Treat. 158, 59\u201365 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"947_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer, R. & Crowley, J. A confidence interval for the median survival time. Biometrics 38, 29\u201341 (1982).","journal-title":"Biometrics"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00947-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00947-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00947-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:34:28Z","timestamp":1776339268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00947-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00947-8","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. received research support from Helsinn Healthcare SA, honoraria from Lilly Deutschland GmbH, Thieme and travel support from Novartis, Lilly Deutschland GmbH, and AstraZeneca. A.H. received grants or contracts from ExactScience, Veracyte, consulting fees from Roche, Novartis, MSD, Agendia, AstraZeneca, GSK, ExactScience, Riemser, Teva, Onkowissen, Lilly, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, DaichiiSankyo, and payment or honoraria for lectures, presentations, speakers bureaus from Roche, Novartis, Lilly, MSD, AstraZeneca, Agendia, Seagen, GSK, ExactScience, Riemser, Teva, Onkowissen, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Eisai, DaichiiSankyo, Thieme, Veracyte, Springer, support for attending meetings from Roche, Novartis, Lilly, AstraZeneca, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, DaichiiSankyo and Participation on Advisory Board from Novartis, Roche, Agendia, Lilly, Gilead, AstraZeneca, Pfizer, MSD, Daiichi Sankyo, GSK, Menarini Stemline, ExactScience, Eisai, Sandoz\/Hexal. N.A. received honoraria for lectures and participation in advisory boards: Gilead, Pfizer, Novartis, and received support for attending meetings from AstraZeneca, Novartis. A.K. received lecture fees from Gilead and Novartis, honoria for written scientific work from Thieme as well as support for attending meetings from Lilly; T.L. received Consulting fees from Roche, Lilly, MSD, honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, Roche, MSD, Novartis, Pfizer, Lilly, GSK, Gilead, AstraZeneca, Daiichi Sankyo, Stemline, Seagen, Support for attending meetings and\/or travel from Pfizer, AstraZeneca, Gilead, Daiichi Sankyo, Stemline, Seagen, MSD, advisory board honoraria from MSD, Roche, Pfizer, Lilly, Myriad, Esai, GSK, Gilead, Daiichi Sankyo, Roche, AstraZeneca; A.E. received lecture honoraria from AstraZeneca. H.S. received honoraria from Pfizer, Novartis, GILEAD, Lilly, Daiichi, Eickeler Veranstaltungen, Novartis, GILEAD. N.T. received honoraria for lectures and advisory boards: Novartis, Exact Sciences, Pfizer, Thieme, AstraZeneca, Grants or contracts from: Novartis, Travel expenses: Novartis, Daiichi sankyo, AstraZeneca, Participation on a Data safety Monitoring Board or Advisory Board from Novartis, Thieme, C.G. received speaker honoraria from Novartis Pharma GmbH and ClinSol GmbH & Co. KG. C.M.T. received honoraria from AstraZeneca and is a shareholder in Curevac N.V. and BioNTech SE. M.B.-P. received grants or contracts from Korean Breast Cancer Society, Eugen & Irmgard Hahn Stiftung, EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, Exact Sciences, Claudia von Schilling Stiftung, Dampft Stiftung, Ehmann Stiftung, Savognin, payment for honoraria or lectures from Roche, Novartis, Pfizer, Pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, Resitu, Pierre Fabre, Exact Sciences, Aurikamed, Stemline, support for attending meetings from Eli Lilly, Exact Sciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche, Stemline. S.Y.B. received institutional grants from Pfizer, Seagen, Daiichi-Sankyo, Gilead, Berlin-Chemie AG, AstraZeneca, Helsinn Healthcare S.A. and personal honoraria for lectures from AstraZeneca. CC.H. received honoraria for lectures from Novartis, Roche, Pfizer, Gilead, AstraZeneca, MSD, Daiichi Sankyo, Eisai, honoraria for participation in advisory boards from Roche, Daiichi Sankyo, MSD, Novartis and support for attending meetings from Daiichi Sankyo. D.L. reports consulting fees, honoraria, payment for expert testimony or support for attending meetings from Eli Lilly, Novartis, Pfizer, Gilead, Daiichi Sankyo, GSK, Loreal, Onkowissen, high5, MSD, AstraZeneca, AbbVie, Genmab. M.P.L reports payments for participation in Advisory Boards \/ Advisory from Novartis, Hexal, Agendia, Endomag, Lilly, MSD, Pfizer, Exact Sciences, Daiichi-Sankyo, Gilead, Roche, Stemline\/ Menari-Group, AstraZeneca, Payment for lectures from Lilly, Roche, MSD, Novartis, Pfizer, Exact Sciences, Daiichi-Sankyo, Gr\u00fcnenthal, GSK, Gilead, AstraZeneca and Eisai, support for attending meetings from Gilead, Daiichi-Sankyo, AstraZeneca and Pfizer, Participation on a Data Safety Monitoring Board or Advisory Board Pfizer PERFORM trial, Novartis BC-CAPTOR-trial, Novartis Caroleen trial and board membership for Deutsche Gesellschaft f\u00fcr Senologie e.V., Deutsche Akademie f\u00fcr Senologie and Participant in the Kommission Mamma der AGO e.V. and Receipt of equipment, materials, drugs, medical writing, gifts or other services from AstraZeneca Pfizer, V.M. received Speaker honoraria: AstraZeneca, arsTempi, Daiichi-Sankyo, Eisai, Pfizer, MSD, Medac, Novartis, Roche, Seagen, Onkowissen, high5 Oncology, Lilly, Medscape, Gilead, Pierre Fabre, iMED Institute, Consultancy honoraria: Roche, Pierre Fabre, PINK, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Seagen, Gilead, Stemline, Institutional research support: Novartis, Roche, Seagen, Genentech, AstraZeneca, Travel grants: Astra Zeneca, Roche, Pfizer, Daiichi Sankyo, Gilead, V.M. is an editorial board member of the journal The Breast. F.-A.T. received consulting fees from GSK, AbbVie, MSD, Payment or honoraria for lectures, presentations, speakers bureaus from AstraZeneca, Roche, Novartis and Support for attending meetings and\/or travel from AbbVie. A.S. received honoraria from Amgen, AstraZeneca, Aurikamed, Bayer, Celgene, ClinSol, Clovis Oncology, coma UroGyn, Connectmedica, Daiichi Sankyo, Gilead, GSK, if-kongress, I-MED, iOMEDICO, Lilly, MCI Deutschland, med publico, Menarini Stemline, Metaplan, MSD, Mylan, NeoConnect, NanoString Technologies, Novartis, Onkowissen, Pfizer, Pierre Fabre, promedicis, Roche, Seagen, streamedup, SYNLAB, Tesaro and travel support from AstraZeneca, Celgene, Daiichi Sankyo, Gilead, Pfizer, Roche; M.B-P. received honoraria for lectures and advisory boards: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, resitu, Pierre Fabre, ExactSciences, Aurikamed. Study support: Korean Breast Cancer Society, Eugen & Irmgard Hahn Stiftung, EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, ExactSciences, Claudia von Schilling Stiftung, Damp Stiftung, Ehmann Stiftung Savognin. Travel expenses: Eli Lilly, ExactSciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche, Stemline. A.R. received honoraria for lectures: Roche, Pfizer, Novartis, Celgen, LEO Pharma, Novartis, ExactSciences, Pierre Fabre, Lilly, Seagen, Targos and honoraria for Participation on a Data Safety Monitoring Board or Advisory Board from Roche, Daiichi Sankyo, AstraZeneca, Pfizer, Celgen, Eisai, Novartis, MSD, Hexal, Amgen, Exact Sciences, Pierre Fabre, RG. Advisory Boards: Roche, AstraZeneca, Pfizer, Celgen, Eisai, Novartis, MSD, Hexal, Amgen, ExactSciences, Pierre Fabre. J.E. received Speakers Bureau, Travel Grants or Advisory Boards: Eli Lilly, Novartis, Pfizer, Gilead, Daiichi Sankyo, GSK, Onkowissen, AstraZeneca, Menarini. T.F. received as consulting fees or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events personal payments from Onkowissen, Medconcept, Payments to institution from AstraZeneca, Daichii Sankyo, Roche, Novartis, Pfizer, AbbVie. MSD, Support for attending meetings and\/or travel from Roche, Daichii Sankyo, Pfizer; S.S. received consulting fees or Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Daiichi-Sankyo, GE HealthCare, Gilead, GSK, Lilly, MSD, Novartis, Pfizer, Roche, Stemline Menarini and support for attending meetings from AstraZeneca, GE HealthCare, Gilead, Lilly, Pfizer, Stemline Menarini. L.L.M. received fees for speaking engagements and accommodation expenses in connection with congress participations from Roche, Pfizer, Lilly Pharma, Daiichi Sankyo, AstraZeneca, Onkowissen, Gilead, Novartis. W.W.J. received research Grants and\/or honoraria from AstraZeneca, Cellgene, Chugai, Daiichi Sankyo, Eisai, ExactScience, Gilead, GSK, Guardant Health, Janssen, Lilly, Menarini Stemline, MSD, NeoGenomics, Novartis, Pfizer, Roche, Sanofi-Aventis, Seagen. M.W. received Grants or contracts from Novartis, Consulting fees from AstraZeneca, Daichi-Sankyo, Pfizer, Novartis, Roche, Ethicon, Onkowissen, Menari, Storz, PlantTec, honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Daichi-Sankyo, Pfizer, Novartis, Roche, Ethicon, Onkowissen, Menari, Storz, PlantTec, Payment for expert testimony from Astra-Zeneca, Daichi-Sankyo, Pfizer, Novartis, Roche, Menari, fees for participation on a Data Safety Monitoring Board or Advisory Board from Astra-Zeneca, Daichi-Sankyo, Pfizer, Novartis, Roche, Ethicon, Onkowissen, Menari, Storz, PlantTec and is an ESGE AdBoard member, AGE Steering Board, Member of AGO \u201cuterus committee\u201d, Coordinator S2-LL Uterine sarcomas, P.A.F. has received institutional funding from BioNTech, Cepheid and Pfizer and peronal honoraria from Novartis, Pfizer, Roche, Daiichi Sankyo, AstraZeneca, Lilly, Eisai, Merck Sharp & Dohme, Pierre Fabre, SeaGen, Agendia, Sanofi Aventis, Gilead and Mylan for consulting, participation in advisory boards and steering committees and\/or lectures. His institution conducts research for Novartis. C.M. received consulting fees from AbbVie, Celgene\/BMS, Pfizer, Nordic Pharma, honoraria for lectures or presentations from Daiichi Sankyo, Novartis, Lilly and support for attending meetings and\/or travel from Brustkrebs Deutschland eV, Novartis, Roche, Mundipharma, Amgen, Servier Deutschland GmbH, AbbVie. The other authors do not have a competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}